IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
10 déc. 2024 07h00 HE
|
IN8bio, Inc
IN8bio Reports Continued Progression-Free Survival in Phase 1 Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 ASH Conference
IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
02 déc. 2024 07h00 HE
|
IN8bio, Inc
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William...
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
25 nov. 2024 07h00 HE
|
IN8bio, Inc
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
12 nov. 2024 16h26 HE
|
IN8bio, Inc
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
12 nov. 2024 07h00 HE
|
IN8bio, Inc
IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
05 nov. 2024 09h00 HE
|
IN8bio, Inc
IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
IN8bio Announces Pricing of $12.4 Million Private Placement
01 oct. 2024 08h00 HE
|
IN8bio, Inc
IN8bio Announces Pricing of $12.4 Million Private Placement
IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia
04 sept. 2024 16h01 HE
|
IN8bio, Inc
IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia
IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
29 août 2024 06h05 HE
|
IN8bio, Inc
IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100
12 août 2024 08h05 HE
|
IN8bio, Inc
IN8bio Announces FDA Guidance for Registrational Trial of INB-100 as 100% of AML Patients remain in Complete Remission